Viveve Medical Financial Statements (VIVE)
|
|
|
|
Report date
|
|
|
19.03.2020 |
18.06.2020 |
29.06.2020 |
18.03.2021 |
17.03.2022 |
|
10.11.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
6.57 |
6.57 |
6.57 |
5.48 |
6.43 |
|
6.83 |
|
Operating Income, bln rub |
|
|
-29.9 |
-29.9 |
-29.9 |
-18.5 |
-21.6 |
|
-21.1 |
|
EBITDA, bln rub |
? |
|
-28.9 |
-28.9 |
-30.7 |
-18.5 |
-20.6 |
|
-20.6 |
|
Net profit, bln rub |
? |
|
-46.7 |
-46.7 |
-46.7 |
-21.2 |
-22.0 |
|
-23.9 |
|
|
OCF, bln rub |
? |
|
-31.2 |
-31.2 |
-31.2 |
-15.2 |
-12.9 |
|
-16.2 |
|
CAPEX, bln rub |
? |
|
1.09 |
1.09 |
1.09 |
0.781 |
0.456 |
|
0.595 |
|
FCF, bln rub |
? |
|
-32.3 |
-32.3 |
-32.3 |
-16.0 |
-13.3 |
|
-16.8 |
|
Dividend payout, bln rub
|
|
|
0.378 |
0.378 |
0.378 |
0.000 |
0.000 |
|
4.69 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
-19.6% |
|
|
OPEX, bln rub |
|
|
31.0 |
31.0 |
31.0 |
18.8 |
22.2 |
|
22.3 |
|
Cost of production, bln rub |
|
|
5.55 |
5.55 |
5.55 |
5.18 |
5.81 |
|
5.71 |
|
R&D, bln rub |
|
|
8.59 |
8.59 |
8.59 |
5.13 |
9.67 |
|
8.72 |
|
Interest expenses, bln rub |
|
|
4.35 |
4.35 |
4.35 |
0.910 |
1.000 |
|
1.11 |
|
|
Assets, bln rub |
|
|
27.0 |
27.0 |
27.0 |
16.6 |
25.9 |
|
12.2 |
|
Net Assets, bln rub |
? |
|
16.5 |
16.5 |
16.5 |
6.97 |
15.1 |
|
1.18 |
|
Debt, bln rub |
|
|
4.25 |
4.25 |
4.25 |
5.86 |
5.35 |
|
5.88 |
|
Cash, bln rub |
|
|
13.3 |
13.3 |
13.3 |
6.52 |
19.2 |
|
5.91 |
|
Net debt, bln rub |
|
|
-9.06 |
-9.06 |
-9.06 |
-0.66 |
-13.8 |
|
-0.03 |
|
|
Ordinary share price, rub |
|
|
12.6 |
12.6 |
12.6 |
4.70 |
1.14 |
|
0.907 |
|
Number of ordinary shares, mln |
|
|
0.125 |
0.125 |
0.125 |
1.57 |
10.1 |
|
10.7 |
|
|
Market cap, bln rub |
|
|
2 |
2 |
2 |
7 |
12 |
|
10 |
|
EV, bln rub |
? |
|
-7 |
-7 |
-7 |
7 |
-2 |
|
10 |
|
Book value, bln rub |
|
|
17 |
17 |
17 |
7 |
15 |
|
1 |
|
|
EPS, rub |
? |
|
-374.4 |
-374.4 |
-374.4 |
-13.5 |
-2.18 |
|
-2.24 |
|
FCF/share, rub |
|
|
-259.0 |
-259.0 |
-259.0 |
-10.2 |
-1.32 |
|
-1.58 |
|
BV/share, rub |
|
|
132.4 |
132.4 |
132.4 |
4.43 |
1.49 |
|
0.11 |
|
|
EBITDA margin, % |
? |
|
-440.3% |
-440.3% |
-467.2% |
-337.6% |
-320.8% |
|
-301.4% |
|
Net margin, % |
? |
|
-711.4% |
-711.4% |
-711.4% |
-387.6% |
-342.8% |
|
-350.4% |
|
FCF yield, % |
? |
|
-2 056% |
-2 056% |
-2 056% |
-216.5% |
-115.9% |
|
-174.0% |
|
ROE, % |
? |
|
-282.8% |
-282.8% |
-282.8% |
-304.5% |
-146.2% |
|
-2 020% |
|
ROA, % |
? |
|
-173.2% |
-173.2% |
-173.2% |
-127.7% |
-85.0% |
|
-196.8% |
|
|
P/E |
? |
|
-0.03 |
-0.03 |
-0.03 |
-0.35 |
-0.52 |
|
-0.40 |
|
P/FCF |
|
|
-0.05 |
-0.05 |
-0.05 |
-0.46 |
-0.86 |
|
-0.57 |
|
P/S |
? |
|
0.24 |
0.24 |
0.24 |
1.35 |
1.79 |
|
1.42 |
|
P/BV |
? |
|
0.10 |
0.10 |
0.10 |
1.06 |
0.76 |
|
8.17 |
|
EV/EBITDA |
? |
|
0.26 |
0.26 |
0.24 |
-0.36 |
0.11 |
|
-0.47 |
|
Debt/EBITDA |
|
|
0.31 |
0.31 |
0.30 |
0.04 |
0.67 |
|
0.00 |
|
|
R&D/CAPEX, % |
|
|
790.2% |
790.2% |
790.2% |
656.2% |
2 120% |
|
1 466% |
|
|
CAPEX/Revenue, % |
|
|
16.6% |
16.6% |
16.6% |
14.3% |
7.10% |
|
8.72% |
|
| Viveve Medical shareholders |
